Under construction – not a live service
Sign in
Taking peoplePhase 1

Tests a CCR8 antibody alone and with PD-1 therapy in advanced solid tumors

Tests denikitug, alone or with anti-PD-1 therapy, in adults with advanced solid tumors.

Plain-language title generated from the registry record
Registry title: A Phase 1 Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Denikitug (GS-1811), an Afucosylated Anti-CCR8 Monoclonal Antibody, as Monotherapy and in Combination With an Anti–PD-1 Monoclonal Antibody in Adults With Advanced Solid Tumors

Key facts

Where
Barcelona, Madrid, Pamplona, and Pozuelo de Alarcón, SpainSee the 5 sites
Phase
Phase 1

AI summary: who the study is looking for

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with advanced solid tumors: head and neck squamous cell carcinoma, non-small-cell lung cancer, gastric or esophagogastric junction adenocarcinoma, or microsatellite stable metastatic colorectal cancer.

Age
18 years or older
Sex
All sexes can join.
Disease stage
Advanced solid tumors, including head and neck squamous cell carcinoma, non-small-cell lung cancer, gastric and esophagogastric junction adenocarcinoma, and microsatellite stable metastatic colorectal cancer.

Main reasons for not taking part

  • Healthy volunteers cannot join.

Read by machine on 9 November 2026.

Where in Spain

  • Hospital Universitari Vall d'HebronBarcelona, SpainNo longer taking part
  • Hospital Universitario 12 de OctubreMadrid, SpainNo longer taking part
  • MD Anderson Cancer CenterMadrid, SpainNo longer taking part
  • Clínica Universidad de navarraPamplona, SpainNo longer taking part
  • Hospital Universitario Quironsalud MadridPozuelo de Alarcón, SpainNo longer taking part

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Trial details

Who runs it
Gilead Sciences Inc.
Trial code
NCT05007782EU 2022-501684-40-00
Record updated
21 September 2026